News related to Remicade (Infliximab) and/or conditions it is approved for
Remicade Phase 3 data show long-term psoriasis response
Source: The Doctors Lounge - Dermatology
Findings from two Phase 3 studies show high-level, sustained response with maintenance therapy.
Remsima (infliximab) accepted for restricted use in NHS Scotland by the Scottish Medicines Consortium
Source: Arthritis / Rheumatology News From Medical News Today [2015.03.11]
Patients in Scotland suffering from inflammatory conditions including rheumatoid arthritis (RA), Crohn's Disease (CD), ulcerative colitis (UC), and psoriasis will now have access to a new wave of...
Hospira launches first biosimilar monoclonal antibody (mAb) Inflectra (infliximab) in the UK
Source: Arthritis / Rheumatology News From Medical News Today [2015.02.27]
Hospira, Inc., a world leader in the development of biosimilar therapies, recently announced the UK launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab).
Celltrion launches world's first biosimilar monoclonal antibody Remsima in 12 new European markets
Source: Arthritis / Rheumatology News From Medical News Today [2015.02.26]
Celltrion Healthcare has announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden...